Monomethyl auristatin E | CAS:474645-27-7

Chemscene社は、高品質な低分子化合物を提供しているメーカーです。
Chemscene社のMonomethyl auristatin E(CAS:474645-27-7)をご紹介します。

※本製品は研究用です。研究用以外には使用できません。

Name:Monomethyl auristatin E; Vedotin; MMAE
Cat. No. :CS-0837
CAS No. :474645-27-7
Formula:C39H67N5O7
M. Wt. : 717.98
Solubility:DMSO: ≥ 48 mg/mL

Monomethyl auristatin E (MMAE) is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin, and also shows inhibition of antibody-drug conjugates (ADCs) activity. IC50 & Target: Microtubule[1]In Vitro: Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].In Vivo: Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models[2].

Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.